New Yorkmed spa & injectable regulations
What’s changing for med spas and injectors in New York — GLP-1 compounding, scope-of-practice, and enforcement — plus the federal FDA and Federal Register actions that apply in New York. Med Spa Radar monitors it all and tells you, in plain language, what changed and what to do.
Latest New York changes
No New York-specific changes have crossed our radar yet — we’re actively monitoring the New York legislature and licensing boards. The federal changes below apply to every New York practice today.
Federal changes that apply in New York
FDA and Federal Register actions are nationwide — they govern New York practices too.
- CRITICALFEDERALFDA Enforcement2025-09-10
FDA recall (Class II): Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy
FDA recalls compounded GLP-1 product for being subpotent.
- CRITICALFEDERALFDA Enforcement2025-08-13
FDA recall (Class II): Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Steri…
FDA recalls compounded GLP-1 product; check your stock now!
- CRITICALFEDERALFDA Enforcement2026-01-07
FDA recall (Class II): Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880…
FDA recalls Wegovy; med spas must check supplies!
- CRITICALFEDERALFDA Enforcement2026-03-11
FDA recall (Class II): Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061,…
FDA recalls Semaglutide for sterility issues—act now!
- CRITICALFEDERALFDA Enforcement2026-01-07
FDA recall (Class II): Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 B…
FDA recalls Wegovy due to safety concerns; med spas must act.
- CRITICALFEDERALFDA Enforcement2025-07-02
FDA recall (Class II): Semaglutide, 2.5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80…
FDA recalls GLP-1 product over sterility issues.
What we monitor in New York
- New York legislature — bills on injectables, GLP-1s & scope of practice
- New York Board of Nursing — injector scope & delegation
- New York Medical Board — physician supervision & ownership rules
- New York Board of Pharmacy — compounding & 503A/503B
- U.S. FDA — enforcement, warning letters, recalls, shortages
- Federal Register — new rules on compounding & aesthetics
New York med spa compliance — FAQ
- Where do New York med spa and injectable regulations come from?
- New York med spas and injectors are governed by a mix of state and federal authorities — the New York legislature, and the state's boards of nursing, medicine, and pharmacy, alongside federal bodies like the FDA and the Federal Register. Med Spa Radar monitors all of them for New York and flags what changed in plain language.
- Does the FDA's GLP-1 compounding guidance apply in New York?
- Yes — federal FDA actions on GLP-1 compounding (semaglutide, tirzepatide) apply nationwide, including in New York. We track those federal changes alongside any New York-specific rules so you see the full picture for your practice.
- How do I keep up with New York regulatory changes?
- Med Spa Radar sends a free weekly Brief on what changed across New York, the FDA, and the Federal Register. Members get the exact "what to do" for their states in real time. It's regulatory monitoring, not legal advice.
Never miss a New York change
Get the free weekly Brief on what changed across New York, the FDA, and the Federal Register. Members get the exact what-to-do, in real time, for their states.
Get the free Brief →← All states · Regulatory monitoring, not legal advice.